Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4004MR)

This product GTTS-WQ4004MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4004MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6044MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ10565MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ6497MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ5292MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ8147MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ10043MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ8426MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ6663MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DMUC5754A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW